Rare emergence of delamanid resistance in multidrug-/rifampicin-resistant tuberculosis patients receiving delamanid-containing regimens: a prospective multicentric study in China

Abstract Background Delamanid (DLM) is a promising drug recommended for treatment of multidrug-/rifampicin-resistant tuberculosis (MDR/RR-TB). However, there are very little data about the emergence of drug resistance in patients with the use of DLM-containing regimens. The study aimed to monitor the dynamics of susceptibility of MTB to DLM and investigate the potential mechanism conferring decreased susceptibility. Methods A prospective cohort study was conducted, enrolling MDR/RR-TB patients with culture-confirmed diagnoses across 10 study sites. Serial sputum samples were collected from participants receiving DLM-containing regimens at baseline (treatment initiation), week 2, week 4, and every 4 weeks thereafter until treatment completion. The in vitro susceptibility of Mycobacterium tuberculosis isolates to DLM was assessed using the BACTEC MGIT 960 system. Results A total of 263 MDR/RR-TB patients were included from 2020 to 2024 in the present study, favorable outcomes were recorded in 187 patients (71.1%). The distribution of minimal inhibit concentration (MIC) for a bacterial population to DLM was unimodal, and most isolates tested had a MIC value of < 0.015 µg/mL. The MIC 50 and MIC 90 of MTB isolates were 0.03 and 0.06 µg/mL, respectively. Using the 0.12 µg/mL as a proposed epidemiological cutoff value, the resistance to DLM was found in 0.76% (2/263) of MTB isolates and no mutations were identified within loci conferring DLM resistance. Additionally, the remaining 81 (30.8%) with serial isolates were included in our analysis. 70 out of 81 patients exhibited no change in DLM MICs. In contrast, the reduced susceptibility to DLM was noted in 11 patients, defined as no less than 2-fold increase in MIC value compared with that of baseline. Conclusions Primary DLM resistance was rare (0.76%), and resistance emergence during treatment was infrequent, though some cases of reduced susceptibility were observed.

Authors

Institutions

Publication Details

Journal
Annals of Clinical Microbiology and Antimicrobials
Published
2026-07-02
DOI
https://doi.org/10.1186/s12941-025-00820-9
Primary Topic
Tuberculosis Research and Epidemiology
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Rare emergence of delamanid resistance in multidrug-/rifampicin-resistant tuberculosis patients receiving delamanid-containing regimens: a prospective multicentric study in China

Yuanhong Xu, Zhongfeng Huang, Long Jin, Yufeng Wang et al.
Annals of Clinical Microbiology and Antimicrobials
Tuberculosis Research and Epidemiology
article

Rare emergence of delamanid resistance in multidrug-/rifampicin-resistant tuberculosis patients receiving delamanid-containing regimens: a prospective multicentric study in China

Yuanhong Xu, Zhongfeng Huang, Long Jin, Yufeng Wang, Yi-Jen Huang, Yi Pei, Ruixia Liang, Lin Wang, Shanshan Li, Yu Pang, Mengqiu Gao, Liang Li, Yuanyuan Shang, Liang Yan, Wei Shu, Qingshan Cai
article en

Abstract

Abstract Background Delamanid (DLM) is a promising drug recommended for treatment of multidrug-/rifampicin-resistant tuberculosis (MDR/RR-TB). However, there are very little data about the emergence of drug resistance in patients with the use of DLM-containing regimens. The study aimed to monitor the dynamics of susceptibility of MTB to DLM and investigate the potential mechanism conferring decreased susceptibility. Methods A prospective cohort study was conducted, enrolling MDR/RR-TB patients with culture-confirmed diagnoses across 10 study sites. Serial sputum samples were collected from participants receiving DLM-containing regimens at baseline (treatment initiation), week 2, week 4, and every 4 weeks thereafter until treatment completion. The in vitro susceptibility of Mycobacterium tuberculosis isolates to DLM was assessed using the BACTEC MGIT 960 system. Results A total of 263 MDR/RR-TB patients were included from 2020 to 2024 in the present study, favorable outcomes were recorded in 187 patients (71.1%). The distribution of minimal inhibit concentration (MIC) for a bacterial population to DLM was unimodal, and most isolates tested had a MIC value of < 0.015 µg/mL. The MIC 50 and MIC 90 of MTB isolates were 0.03 and 0.06 µg/mL, respectively. Using the 0.12 µg/mL as a proposed epidemiological cutoff value, the resistance to DLM was found in 0.76% (2/263) of MTB isolates and no mutations were identified within loci conferring DLM resistance. Additionally, the remaining 81 (30.8%) with serial isolates were included in our analysis. 70 out of 81 patients exhibited no change in DLM MICs. In contrast, the reduced susceptibility to DLM was noted in 11 patients, defined as no less than 2-fold increase in MIC value compared with that of baseline. Conclusions Primary DLM resistance was rare (0.76%), and resistance emergence during treatment was infrequent, though some cases of reduced susceptibility were observed.

Annals of Clinical Microbiology and AntimicrobialsVol. 25(1)
Kunming Third People's Hospital (CN), Changsha Central Hospital (CN), Center for Tuberculosis Control of Guangdong Province (CN), Beijing Chest Hospital (CN), Heilongjiang Center for Tuberculosis Control and Prevention (CN), Jiangxi Chest Hospital (CN), Guiyang University (CN), Guangxi Zhuang Autonomous Region Brain Hospital (CN), Henan Provincial Chest Hospital (CN), Public Health Clinical Center of Chengdu (CN), Hangzhou Red Cross Hospital (CN)
Beijing Municipal Science and Technology Commission
Good health and well-being
Openalex Percentile: Top 8%
Tuberculosis Research and Epidemiology
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.